Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25322404 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25321566 | 0.82 | — | — | |
| SCHEMBL25321569 | 0.82 | — | — | |
| SCHEMBL30551540 | 0.82 | KCNH2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25323613 | 0.82 | KCNH2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25323614 | 0.82 | KCNH2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24365550 | 0.80 | DRD2 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL24364132 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29081771 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24233784 | 0.76 | HTR2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | CHRNB2 2937/4885CHRNB4 3670/4885CHRNA3 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.